GleamWall
中文EN

DWTX Dogwood Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1818844 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY34.1%
TTM EPS YoY140.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-70.5%
ROA-30.0%
ROIC (approx.)-78.2%
Asset turnover—

Leverage & solvency

Liabilities / assets15.2%
Debt / equity0.00x
Current ratio2.78x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.65x
Accruals ratio-10.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$100,000———————
Cost of revenue$88,104———————
Gross profit$11,896———————
R&D expense$3.35M$3.25M$2.67M$2.34M$14.52M$2.57M$2.44M$2.32M
SG&A expense$1.58M$1.63M$2.41M$1.47M$1.29M$1.35M$1.99M$5.23M
Operating income-$4.92M-$14.06M-$5.08M-$3.81M-$15.81M-$3.92M-$4.43M-$7.54M
Pretax income-$4.88M-$14.01M-$4.99M-$3.75M-$15.75M-$3.81M-$10.73M-$7.73M
Net income-$4.88M-$11.53M-$4.99M-$3.78M-$15.74M-$3.81M-$10.92M-$7.73M
EBITDA———-$3.81M-$15.84M-$3.91M-$4.41M—
EPS (basic)-0.14-0.34-0.15—-8.20-1.99-8.45—
EPS (diluted)-0.14-0.34-0.15—-8.20-1.99-8.45—
Weighted avg. shares (diluted)34.13M34.13M33.54M—1.92M1.91M1.44M—
Balance sheet
Cash & equivalents$4.95M$9.61M$13.23M$6.52M$10.13M$13.40M$17.54M$14.85M
Current assets$6.04M$11.03M$15.00M$8.43M$11.66M$14.70M$19.16M$16.54M
PP&E, net$12,320$12,301$12,541$12,754$15,293$16,179$15,899$16,811
Goodwill$11.98M$11.96M$12.19M$12.40M$12.21M$12.46M$11.82M$11.81M
Intangibles$57.44M$57.35M$67.83M$68.99M$67.92M$69.30M$65.77M$65.71M
Total assets$75.61M$80.50M$95.21M$90.17M$91.99M$96.69M$96.98M$94.31M
Current liabilities$2.17M$2.83M$2.56M$3.06M$2.60M$1.89M$2.58M$3.18M
Total liabilities$11.47M$12.13M$14.58M$15.27M$14.61M$14.15M$14.24M$30.03M
Shareholders' equity$64.13M$68.37M$80.62M$74.90M$7.26M$6.88M$7.09M-$10.12M
Shares outstanding34.13M33.63M33.40M29.74M2.29M1.91M1.91M1.33M
Cash flow statement
Operating cash flow-$4.64M-$3.61M-$4.59M-$3.64M-$3.27M-$4.03M-$4.68M-$6.13M
Financing cash flow$50$23$11.29M$32,561$0-$120,133$7.37M$15.32M
Depreciation & amortization———$0-$32,215$17,256$17,022—
Stock-based compensation$558,403$543,203$449,419$157,860$48,281$65,027$84,474$93,802

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.